AAUM (Average Assets Under Management) of ₹84.60 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 60.6% | 62.5% | ▲ +2.0% |
| Healthcare Services | 27.0% | 27.1% | ▲ +0.2% |
| Chemicals & Petrochemicals | 5.4% | 5.6% | ▲ +0.2% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 62.5% | 62.6% | ● +0.1% |
| Healthcare Services | 27.1% | 29.1% | ▲ +2.0% |
| Chemicals & Petrochemicals | 5.6% | 5.2% | ▼ -0.4% |
Comparing Jun 2026 → Jul 2026
| # | Stock | Sector | Weight (Jul 2026) |
|---|---|---|---|
| 1 | Cohance Lifesciences Limited ₹2.32 Cr |
Pharmaceuticals & Biotechnology | 2.37% |
| # | Stock | Sector | Last Weight (Jun 2026) |
|---|---|---|---|
| 1 | Acutaas Chemicals Ltd ₹2.22 Cr |
Pharmaceuticals & Biotechnology | 2.40% |
| 2 | Anthem Biosciences Limited ₹1.95 Cr |
Pharmaceuticals & Biotechnology | 2.11% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹9.25 Cr |
Pharmaceuticals & Biotechnology | 7.17% | 9.47% | +2.30% |
| 2 | Aster DM Healthcare Limited ₹4.56 Cr |
Healthcare Services | 3.18% | 4.67% | +1.49% |
| 3 | Max Healthcare Institute Limited ₹2.78 Cr |
Healthcare Services | 2.05% | 2.84% | +0.79% |
| 4 | Mankind Pharma Limited ₹3.04 Cr |
Pharmaceuticals & Biotechnology | 2.36% | 3.12% | +0.76% |
| 5 | Torrent Pharmaceuticals Limited ₹6.73 Cr |
Pharmaceuticals & Biotechnology | 6.55% | 6.89% | +0.34% |
| 6 | Artemis Medicare Services Limited ₹2.79 Cr |
Healthcare Services | 2.68% | 2.86% | +0.18% |
| 7 | Sun Pharmaceutical Industries Limited ₹10.44 Cr |
Pharmaceuticals & Biotechnology | 10.55% | 10.69% | +0.14% |
| 8 | Metropolis Healthcare Limited ₹2.76 Cr |
Healthcare Services | 2.76% | 2.82% | +0.06% |
| 9 | Global Health Limited ₹3.13 Cr |
Healthcare Services | 3.16% | 3.20% | +0.04% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Navin Fluorine International Limited ₹5.08 Cr |
Chemicals & Petrochemicals | 5.58% | 5.20% | -0.38% |
| 2 | Fortis Healthcare Limited ₹4.07 Cr |
Healthcare Services | 4.45% | 4.16% | -0.29% |
| 3 | Aurobindo Pharma Limited ₹4.91 Cr |
Pharmaceuticals & Biotechnology | 5.30% | 5.02% | -0.28% |
| 4 | Zydus Lifesciences Limited ₹4.79 Cr |
Pharmaceuticals & Biotechnology | 5.11% | 4.90% | -0.21% |
| 5 | Gland Pharma Limited ₹3.51 Cr |
Pharmaceuticals & Biotechnology | 3.79% | 3.60% | -0.19% |
| 6 | Onesource Specialty Pharma Limited ₹2.43 Cr |
Pharmaceuticals & Biotechnology | 2.67% | 2.49% | -0.18% |
| 7 | Neuland Laboratories Limited ₹5.44 Cr |
Pharmaceuticals & Biotechnology | 5.74% | 5.57% | -0.17% |
| 8 | Apollo Hospitals Enterprise Limited ₹6.46 Cr |
Healthcare Services | 6.77% | 6.62% | -0.15% |
| 9 | Glenmark Pharmaceuticals Limited ₹2.68 Cr |
Pharmaceuticals & Biotechnology | 2.86% | 2.74% | -0.12% |
| 10 | Dr Agarwals Health Care Limited ₹1.89 Cr |
Healthcare Services | 2.05% | 1.94% | -0.11% |
22 stocks — Jul 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹10.44 Cr |
Pharmaceuticals & Biotechnology |
10.69%
|
|
| 2 |
₹9.25 Cr |
Pharmaceuticals & Biotechnology |
9.47%
|
|
| 3 |
₹6.73 Cr |
Pharmaceuticals & Biotechnology |
6.89%
|
|
| 4 |
₹6.46 Cr |
Healthcare Services |
6.62%
|
|
| 5 |
₹5.44 Cr |
Pharmaceuticals & Biotechnology |
5.57%
|
|
| 6 |
₹5.08 Cr |
Chemicals & Petrochemicals |
5.20%
|
|
| 7 |
₹4.91 Cr |
Pharmaceuticals & Biotechnology |
5.02%
|
|
| 8 |
₹4.79 Cr |
Pharmaceuticals & Biotechnology |
4.90%
|
|
| 9 |
₹4.56 Cr |
Healthcare Services |
4.67%
|
|
| 10 |
₹4.07 Cr |
Healthcare Services |
4.16%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.